Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings

Mercadante, Sebastiano; Aielli, Federica; Adile, Claudio; Ferrera, Patrizia; Valle, Alessandro; Cartoni, Claudio; Pizzuto, Massimo; Caruselli, Amanda; Parsi, R A; Cortegiani, Andrea; Masedu, Francesco; Valenti, Marco; Ficorella, Corrado; Porzio, Giampiero

doi:10.1016/j.jpainsymman.2015.06.018

Cited by 80 publications

(78 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of various treatments on the initiation and maintenance of insomnia is likely to be mediated, at least in part, through the adverse effects of treatment. Two such common adverse effects, night sweats/hot flashes and nocturia, cause night time waking [27,28,42,45,47,48] . These symptoms have also been proposed to have an additive effect whereby when men wake up due to night doi: 10.18282/amor.v2.i2.94 sweats, they may also empty their bladder, thus prolonging the length of time they are awake at night and possibly making it more difficult to resume sleep [47] .…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, the prevalence of insomnia syndrome was similar among men with localised prostate cancer (18%) and women with breast cancer (19%) [42] . Furthermore, among patients with advanced cancer, a diagnosis of prostate, breast, lung, and gastrointestinal cancer was associated with increased likelihood of insomnia [28] . Insomnia among prostate cancer patients was also reportedly higher than in the general population [19] .…”

Section: Insomnia and Different Cancer Sitesmentioning

confidence: 98%

“…Unlike populations without cancer, insomnia is inversely related with age in patients with cancer at mixed sites [21,23,28,44] and also among men with prostate cancer [42,49] . Younger men are also more likely to develop insomnia syndrome [42] , suggesting that younger men may have more trouble adjusting to their 'new normality' and consequently, are more susceptible to chronic sleeping difficulties.…”

Section: Predisposing Factors Agementioning

confidence: 99%

“…However, insomnia was consistently reported to be higher in men treated with ADT or radiotherapy or a combination of these modalities [14,25,44,45,[47][48][49][50] . The effects of various treatments on the initiation and maintenance of insomnia have been shown to be mediated through the treatment side effects experienced by men with prostate cancer, particularly night sweats/hot flashes and nocturia [27,28,42,45,47,48] . An interaction between these symptoms has also been proposed whereby when men wake up due to night sweats, they also empty their bladder, thus prolonging the length of time they are awake at night [47] .…”

Section: Cancer Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Are we sleeping on the job? Insomnia among men with prostate cancer

Drummond

2016

Adv Mod Oncol Res

View full text Add to dashboard Cite

Prostate cancer is one of the most commonly diagnosed cancers in men and almost half of male cancer survivors in the US have had a prostate cancer diagnosis. Insomnia is common among cancer patients and survivors. There is evidence that cognitive behavioural therapy can be used to effectively manage insomnia among women with breast cancer. The aim of this review was to investigate the prevalence, risk factors and management of insomnia among men with prostate cancer. The effect of insomnia on the psychological health and health-related quality of life of these patients and/or survivors is also discussed. Increased awareness and knowledge of this symptom among men with prostate cancer may facilitate improved diagnosis, and management of insomnia in this large population. This in turn may improve the health-related quality of life of these men. Therefore, research into the effective management of insomnia among men with prostate cancer is essential.Keywords: prostate cancer; insomnia; androgen deprivation therapy; radiotherapy; health-related quality of life; depression; anxiety

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Insomnia and Different Cancer Sitesmentioning

confidence: 98%

Section: Predisposing Factors Agementioning

confidence: 99%

Section: Cancer Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Are we sleeping on the job? Insomnia among men with prostate cancer

Drummond

2016

Adv Mod Oncol Res

View full text Add to dashboard Cite

show abstract

“…Insomnia rates for patients with advanced cancer range from 49% to 61% . Sleep is often interrupted by cancer‐related thoughts, as patients worry about disease progression, financial stressors, and treatment outcomes.…”

Section: Introductionmentioning

confidence: 99%

Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer

et al. 2018

View full text Add to dashboard Cite

Objective This study evaluated a three‐session acceptance‐based cognitive behavioral ‐acceptance and commitment therapy (CBT‐ACT) intervention targeting a common symptom cluster in advanced cancer—worry‐insomnia‐depression‐fatigue. Methods Twenty‐eight patients with advanced cancer were randomly assigned to the CBT‐ACT intervention or waitlist. At preintervention, participants completed a psychodiagnostic interview, standardized questionnaires, and a sleep diary. Intervention and waitlist groups were reassessed after 6 weeks, at which point the waitlist group completed the intervention. Results Participants receiving the intervention demonstrated improved sleep efficiency (P = 0.0062, d = 1.08), sleep latency (P = 0.028, d = −0.86), insomnia severity (P = 0.0047, d = −1.18), and worry (P = 0.026, d = −0.89) compared with waitlist controls. They also demonstrated a 7‐point reduction on depression (P = 0.03, d = −0.88), reduced hyperarousal (P = 0.005, d = −1.51), and a decrease in distress (P = 0.032, d = −0.83). Effects were maintained for the whole sample in sensitivity analyses. Effects on uncertainty intolerance approached significance (P = 0.058). No effect was found on fatigue. Conclusions The CBT‐ACT group performed significantly better than the waitlist control group. CBT‐ACT yielded strong effects for worry, sleep, depression, emotional distress, total distress, and hyperarousal. Future studies will enhance the fatigue and uncertainty tolerance components of the intervention.

show abstract

Cancer‐related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double‐blind, noninferiority trial

Eerdekens

Kapanadze

Koch

et al. 2019

European Journal of Pain

View full text Add to dashboard Cite

Background Cancer‐related pain is a growing health problem given the increasing life expectancy of cancer patients. Opioids are commonly used to treat cancer‐related pain, but carry the risk of severe side effects, limiting their use. Cebranopadol is a first‐in‐class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. This trial examined the analgesic efficacy of cebranopadol compared with morphine prolonged release (PR) in patients with moderate‐to‐severe cancer‐related pain. Methods This double‐blind, parallel‐group, multiple‐dose trial was designed as noninferiority trial for efficacy of cebranopadol versus morphine PR. Planned with 524 patients, finally 126 patients were treated for up to 7 weeks (low accrual). The primary efficacy endpoint was the average amount of daily rescue medication intake (morphine immediate release) over the last 2 weeks of treatment. Results For the primary endpoint, noninferiority of cebranopadol with and superiority over morphine PR were demonstrated (Full Analysis Set: ∆[95%CI] = −7.48 mg [−12.05, −2.92]; Per Protocol Set: ∆[95%CI] = −4.67 mg [−9.25, −0.10]). The vast majority of patients (≥75%, either treatment) had clinically relevant pain reduction, and noninferiority on this secondary endpoint was not shown. Mostly used doses were ≤800 μg cebranopadol or ≤120 mg morphine PR daily. A total of 83.1% of patients on cebranopadol and 82.0% on morphine PR experienced treatment‐emergent adverse events. Conclusions Cebranopadol was effective, safe and well tolerated in the dose range tested (200–1,000 μg) in patients suffering from chronic moderate‐to‐severe cancer‐related pain and was superior to morphine PR on the primary endpoint. Significance Cebranopadol presents a new approach to treat cancer pain. The drug candidate was easy to titrate, safe and well tolerated, and as effective as morphine PR in patients suffering from chronic moderate‐to‐severe cancer‐related pain

show abstract

Sleep Disturbances in Patients With Advanced Cancer in Different Palliative Care Settings

Abstract: More than 60% of palliative care patients have relevant sleep disturbances. Several factors associated with sleep disorders have been identified and should prompt physicians to make a careful examination and subsequent treatment of these disturbances.

Cited by 80 publications

References 27 publications

Are we sleeping on the job? Insomnia among men with prostate cancer

Are we sleeping on the job? Insomnia among men with prostate cancer

Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer

Cancer‐related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double‐blind, noninferiority trial

Contact Info

Product

Resources

About